Posted: 8 August 2024
Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce the granting of a key patent in Europe and Japan. The patent, entitled A salt and crystal form of a FAK Inhibitor, describes the specific chemical form of the company’s best-in-class FAK inhibitor narmafotinib.
The Company has received notification from the Japanese Patent Office that the patent was granted in Japan on 18 July 2024, whilst the European Patent Office have advised that the patent will grant in Europe on 28 August 2024.
This patent describes a stable, manufacturable form of narmafotinib that provides improved drug levels upon dosing. Importantly, it is this specific form of the drug that is being developed clinically by the Company, including in the current Phase 2a ACCENT trial in advanced pancreatic cancer.
Amplia’s CEO and Managing Director Dr Chris Burns comments: “The granting of this patent by two of the world’s most respected patent offices bodes well for granting of the patent in other jurisdictions, including the US and Australia. Importantly from a commercial perspective, this patent extends protection for narmafotinib out to at least 2040.”
